3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Pancreatic Neoplasms
1
Neuroectodermal Tumors
1
Nervous System Diseases
1
Neoplasms, Neuroepithelial
1
Neoplasms, Nerve Tissue
1
Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Disease
1
CRC
1
Brain Neoplasms
1
Interventions
Temozolomide
154
Bevacizumab
88
Radiotherapy
75
Radiation
23
Magnetic Resonance Spectroscopy
23
Lomustine
18
Irinotecan
18
pembrolizumab
17
Surgical Procedures, Operative
16
Carmustine
16
Erlotinib Hydrochloride
12
Nivolumab
11
Specimen Handling
10
Aminolevulinic Acid
10
sargramostim
9
Thalidomide
9
Chemotherapy, Adjuvant
9
Carboplatin
9
Drug Therapy
8
Immunoglobulin G
7
Filgrastim
7
Etoposide
7
Disulfides
7
Cilengitide
7
Sunitinib
6
Sorafenib
6
O(6)-benzylguanine
6
Cyclophosphamide
6
antineoplaston AS 2-1
5
antineoplaston A10
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Glioblastoma
×
Oncolytic Virotherapy
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled